Parkinson's Disease Model

Introduction

Parkinson's disease (PD) is a degenerative disorder of the central nervous system commonly seen in middle-aged and elderly individuals. Clinically, it is characterized by resting tremor, bradykinesia, rigidity, and postural instability. Its pathological hallmarks include the loss of dopaminergic neurons in the substantia nigra pars compacta and the formation of Lewy bodies.

Disease models

The SMOC has long been dedicated to research on neurodegenerative diseases and can provide Parkinson's disease mouse models induced by neurotoxins (such as MPTP, 6-OHDA, etc.), as well as related experimental services, to support Parkinson's disease research.

MPTP-induced Parkinson's disease model

1,-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a neurotoxin capable of recapitulating the symptoms of Parkinson's disease (PD) in humans. The MPTP-induced mouse model of PD is a commonly used system for studying the mechanisms of dopaminergic neuron death, due to its relatively simple induction procedure (requiring only intraperitoneal injection) and its consistent neurotoxic effect on dopaminergic neurons.

image.png

Fig1. MPTP-induced Parkinson's disease mouse model.

6-OHDA-induced Parkinson's disease model

6-Hydroxydopamine (6-OHDA) is a hydroxylated derivative of dopamine. It can gradually induce retrograde degeneration of the nigrostriatal dopaminergic (DA) system within a few weeks. Its pathological and biochemical manifestations share many similarities with human Parkinson's disease (PD), including degeneration, death, and loss of dopaminergic neurons in the substantia nigra, as well as glial cell proliferation. The 6-OHDA injection model is one of the most widely used PD models to date and can be applied in studies on PD pathogenesis, evaluation of drug efficacy, gene therapy, and neuroprotective treatment.

image.png

Fig1. 6-OHDA-induced Parkinson's disease mouse model.

南模生物Email Back to top 点击跳转到顶部